|Articles|April 19, 2012

Integration of Mental Health and Substance Abuse Treatment

How would you rate the integration of mental health treatment with addiction treatment? Where is there room for improvement?

How would you rate the integration of mental health treatment with addiction treatment? Where is there room for improvement? We invite you to take the poll and submit your comments below.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Identifying and Treating High Functioning Substance Use Disorder

ByRachel Rohaidy, MD

November 10th 2025

TMS ketamine depression substance use disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

BySteven R. Devore Best, MD

November 5th 2025

Positive FDA Meeting for Abuse Deterrent Fentanyl Patch

ByJessica Walters

October 29th 2025

mice research microbiome reward pathway alcohol use disorder

Impact of Gut Microbiome on Reward Pathways and Alcohol Use Disorder: Insights From Investigators

ByJessica Walters,Carol Kumamoto, PhD,Andrew Day, PhD

October 24th 2025

substance use disorder ADHD sex differences

ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences

ByJessica Walters

October 9th 2025

Latest CME

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Integration of Mental Health and Substance Abuse Treatment

Newsletter

Related Content

Identifying and Treating High Functioning Substance Use Disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

Positive FDA Meeting for Abuse Deterrent Fentanyl Patch

Impact of Gut Microbiome on Reward Pathways and Alcohol Use Disorder: Insights From Investigators

ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences

Latest CME

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Lamotrigine: An Update on Its Role in Bipolar Disorder

FDA Clears Deep Transcranial Magnetic Stimulation for Adolescents With MDD

In Memoriam: 2 Terrible Ironies of Being a Psychiatrist

Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder

Post-Hoc Analysis of Predictive Factors for Response to Adjunctive Cobenfy